(Total Views: 180)
Posted On: 05/16/2024 4:35:56 PM
Post# of 378
NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed in a potentially pivotal GBM study evaluating Berubicin with topline data expected in the first half of 2025. In addition, financial results showed a net loss for the quarter of approximately $3.5 million, down from an estimated $4.9 million net loss for the comparable period in 2023; R&D expenses of $2.4 million with general and administrative expense totaling an estimated $1.1 million, compared to approximately $1.4 million for the same period in 2023; and cash on hand at the end of the quarter totaling about $0.8 million. “With topline results in our ongoing, fully enrolled Berubicin trial for GBM expected in the first half of next year, we continue to plan for success,” said CNS Pharmaceuticals CEO John Climaco in the press release. “Our commitment to our dual mission to bring meaningful treatment options to GBM patients as well as value to all stakeholders remains unwavering.”
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed in a potentially pivotal GBM study evaluating Berubicin with topline data expected in the first half of 2025. In addition, financial results showed a net loss for the quarter of approximately $3.5 million, down from an estimated $4.9 million net loss for the comparable period in 2023; R&D expenses of $2.4 million with general and administrative expense totaling an estimated $1.1 million, compared to approximately $1.4 million for the same period in 2023; and cash on hand at the end of the quarter totaling about $0.8 million. “With topline results in our ongoing, fully enrolled Berubicin trial for GBM expected in the first half of next year, we continue to plan for success,” said CNS Pharmaceuticals CEO John Climaco in the press release. “Our commitment to our dual mission to bring meaningful treatment options to GBM patients as well as value to all stakeholders remains unwavering.”
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
